Becton Dickinson and Company

NYSE BDX

Download Data

Becton Dickinson and Company Enterprise Value to EBITDA (EV/EBITDA) on June 03, 2024: 20.46

Becton Dickinson and Company Enterprise Value to EBITDA (EV/EBITDA) is 20.46 on June 03, 2024, a -5.74% change year over year. The EV/EBITDA ratio compares a company's enterprise value to its EBITDA. It provides insight into the company's valuation relative to its earnings and is commonly used in comparing the relative value of different companies within an industry. A lower ratio suggests a potentially more favorable valuation.
  • Becton Dickinson and Company 52-week high Enterprise Value to EBITDA (EV/EBITDA) is 23.06 on August 14, 2023, which is 12.71% above the current Enterprise Value to EBITDA (EV/EBITDA).
  • Becton Dickinson and Company 52-week low Enterprise Value to EBITDA (EV/EBITDA) is 17.16 on November 09, 2023, which is -16.14% below the current Enterprise Value to EBITDA (EV/EBITDA).
  • Becton Dickinson and Company average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is 20.30.
NYSE: BDX

Becton Dickinson and Company

CEO Mr. Thomas E. Polen Jr.
IPO Date Jan. 1, 1987
Location United States
Headquarters 1 Becton Drive, Franklin Lakes, NJ, United States, 07417-1880
Employees 70,000
Sector Healthcare
Industry Medical instruments & supplies
Description

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Similar companies

ANGO

AngioDynamics Inc

NA

NA

HOLX

Hologic Inc

NA

NA

RGEN

Repligen Corporation

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email